title: Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.
abstract: Pseudomonas aeruginosa is an important prognostic determinant in cystic fibrosis (CF). Little is known however, about P. aeruginosa induced local mucosal and systemic immune responses. Twenty CF children were categorized according to their P. aeruginosa status: (1) chronic lower respiratory tract infection (LRTI), (2) prior successfully treated initial LRTI, (3) isolated upper respiratory tract (URT) colonization, and (4) no known URT colonization or previous LRTI. Their antibody responses, and those of six non-CF disease controls, in serum and bronchoalveolar lavage (BAL) fluid to potential P. aeruginosa vaccine antigens outer membrane protein F (OprF), outer membrane protein H (OprH), catalase A (KatA) and a whole killed cell (WKC) extract were evaluated. Outer membrane protein G (OprG) responses were also measured in blood. Natural exposure, colonization and infection resulted in detectable antibody levels in BAL and serum in all CF groups. Both chronically infected and URT colonized CF children had substantially elevated immunoglobulin A antibody levels in the BAL fluid and sera toward the WKC extract and OprF antigen compared with the other groups of CF children and non-CF controls. The serum levels of specific P. aeruginosa antibodies involving immunoglobulin G and M isotypes increased with chronic LRTI, especially antibody levels to KatA, OprH and WKC extract, which were substantially greater in chronically infected children compared with all other groups. In conclusion, natural exposure, URT colonization and LRTI with P. aeruginosa all induce substantial mucosal and systemic antibody responses to potential vaccine antigens with chronically infected CF children having the highest levels.
authors.affiliation: School of Health Sciences; University of Canberra; Canberra, ACT Australia.
authors.forename: Ryka
authors.initials: R
authors.lastname: Moore
authors.forename: Jennelle M
authors.initials: JM
authors.lastname: Kyd
authors.forename: Rosemary
authors.initials: R
authors.lastname: Carzino
authors.forename: Davide
authors.initials: D
authors.lastname: Armstrong
authors.forename: Keith
authors.initials: K
authors.lastname: Grimwood
authors.forename: Diana C
authors.initials: DC
authors.lastname: Otczyk
authors.forename: Allan W
authors.initials: AW
authors.lastname: Cripps
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis* / Q000097:blood*; D000942:Antigens, Bacterial / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology*; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications; D005260:Female; D006801:Humans; D018928:Immunity, Mucosal; D007070:Immunoglobulin A / Q000032:analysis / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007223:Infant; D008297:Male; D011552:Pseudomonas Infections / Q000276:immunology* / Q000517:prevention & control; D054406:Pseudomonas Vaccines / Q000276:immunology / Q000302:isolation & purification*; D011550:Pseudomonas aeruginosa / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D054406:Pseudomonas Vaccines